Wildcard: Moderna - A Case Study

<p>Moderna has gone from your standard biotech to one of the hot stocks of 2020 over the past few months as the company has worked on a COVID-19 vaccine. Shares are up around 200% since the pandemic hit, and the company has made some moves that seem odd on first pass.</p> <p>We use the company's dramatic rise and position as a clinical-stage business to explore insider selling, raising capital, and the business of biotechs.</p> <p>Stocks: MRNA</p> <p>Check out more of our content here:</p> <div id="1571371200000divider" class="c-virtual_list__item" tabindex="-1" role="listitem"> <ul> <li><a href= "https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" target="_blank" rel="noopener">TMF's podcast portal</a></li> <li><a href="https://www.youtube.com/user/TheMotleyFool" target= "_blank" rel="noopener">YouTube</a></li> <li><a href="https://twitter.com/mfindustryfocus?lang=en" target= "_blank" rel="noopener">Twitter</a></li> <li><a href="https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group</a></li> <li><a href= "https://www.linkedin.com/company/the-motley-fool">LinkedIn</a></li> <li><a href= "https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter</a></li> </ul> </div>